Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 134900
Corporate User License Price USD 6000
Corporate User License Price INR 404700
Site License Price USD 4000
Site License Price INR 269800
Request a Quote

Report Title

Hairy Cell Leukemia-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hairy Cell Leukemia-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hairy Cell Leukemia-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hairy Cell Leukemia-Pipeline Review, H1 2017



Executive Summary

Hairy Cell Leukemia-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia-Pipeline Review, H1 2017, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 2, 1, 3 and 1 respectively.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).

The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hairy Cell Leukemia-Overview

Hairy Cell Leukemia-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hairy Cell Leukemia-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hairy Cell Leukemia-Companies Involved in Therapeutics Development

AbbVie Inc

ARA Healthcare Pvt Ltd

Astellas Pharma Inc

Cellectis SA

F. Hoffmann-La Roche Ltd

Incyte Corp

Juno Therapeutics Inc

MedImmune LLC

Novartis AG

Hairy Cell Leukemia-Drug Profiles

AGS-67E-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARABS-4-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dabrafenib mesylate + trametinib dimethyl sulfoxide-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dezapelisib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibrutinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-50465-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2b-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2b-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itacitinib adipate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

moxetumomab pasudotox-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCART-123-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vadacabtagene leraleucel-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vemurafenib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hairy Cell Leukemia-Dormant Projects

Hairy Cell Leukemia-Discontinued Products

Hairy Cell Leukemia-Product Development Milestones

Featured News & Press Releases

Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours

May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Hairy Cell Leukemia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Hairy Cell Leukemia, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hairy Cell Leukemia-Pipeline by AbbVie Inc, H1 2017

Hairy Cell Leukemia-Pipeline by ARA Healthcare Pvt Ltd, H1 2017

Hairy Cell Leukemia-Pipeline by Astellas Pharma Inc, H1 2017

Hairy Cell Leukemia-Pipeline by Cellectis SA, H1 2017

Hairy Cell Leukemia-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hairy Cell Leukemia-Pipeline by Incyte Corp, H1 2017

Hairy Cell Leukemia-Pipeline by Juno Therapeutics Inc, H1 2017

Hairy Cell Leukemia-Pipeline by MedImmune LLC, H1 2017

Hairy Cell Leukemia-Pipeline by Novartis AG, H1 2017

Hairy Cell Leukemia-Dormant Projects, H1 2017

Hairy Cell Leukemia-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AbbVie Inc, ARA Healthcare Pvt Ltd, Astellas Pharma Inc, Cellectis SA, F. Hoffmann-La Roche Ltd, Incyte Corp, Juno Therapeutics Inc, MedImmune LLC, Novartis AG

Hairy Cell Leukemia Therapeutic Products under Development, Key Players in Hairy Cell Leukemia Therapeutics, Hairy Cell Leukemia Pipeline Overview, Hairy Cell Leukemia Pipeline, Hairy Cell Leukemia Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand